Securities code: Hainan Haiyao Co.Ltd(000566) securities abbreviation: Hainan Haiyao Co.Ltd(000566) Announcement No.: 2022032 Hainan Haiyao Co.Ltd(000566) 2021 annual report summary
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. All directors have attended the meeting of the board of directors to consider this report. Tips on non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of ordinary shares or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors □ applicable √ not applicable. The company plans not to distribute cash dividends, bonus shares or convert accumulation fund into share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Hainan Haiyao Co.Ltd(000566) Stock Code: Hainan Haiyao Co.Ltd(000566)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Shi Lei, Wang Xiaosu
Office address: No. 192, Nanhai Avenue, Xiuying District, Haikou City, Hainan Province
Fax: Gome Telecom Equipment Co.Ltd(600898) 363809
Tel: 089836380609
E-mail Hainan Haiyao Co.Ltd(000566) @haiyao.com.cn. Hainan Haiyao Co.Ltd(000566) @haiyao.com.cn.
2. Introduction to main business or products during the reporting period
(I) operation of the company during the reporting period
1. Focus on the main business and achieve fruitful business performance
In the chemical medicine sector, raw materials and preparations are coordinated to form the linkage effect of long-chain supply and effectively support the company’s production and operation objectives. After the resumption of production, Jiangsu hankuo has formed a number of strategic cooperative relationships to give full play to its production and marketing advantages and stabilize the supply of map raw materials; In the traditional Chinese medicine sector, Hunan Lianqiao Rhizoma Drynariae has made a great breakthrough in market share, and 7 large enterprises have developed traditional Chinese medicine business; In the medical device sector, lisent cochlear implant has increased the clinical application scope under the age of 6, the registration change has been approved, and the product adaptability has been widened. In 2021, the revenue has increased by 15% year-on-year, and the profit has increased significantly compared with the same period last year.
2. Adhere to innovation and steadily promote R & D projects
The company vigorously maintained the R & D investment intensity, steadily promoted the clinical research of innovative drugs, the R & D of generic drugs and the consistency evaluation, and actively promoted the R & D platform of lisent cochlear implant.
The two national major new drug creation projects are progressing smoothly. The national class 1.1 new drug flufenidone capsule project against liver fibrosis has completed the phase I clinical study, obtained the summary report, and started the phase II clinical trial. About 40 clinical sub centers have basically passed the ethical review, more than 10 have held the kick-off meeting, and the phase II clinical cases have been enrolled; The pinegabine project for the treatment of intractable epilepsy has started phase I clinical trial, completed the clinical study of single dose administration, and communicated the clinical scheme of multiple administration with the clinical center.
In 2021, the generic drug tigrelol has obtained the drug approval; The registration application of desloratadine oral solution was completed; Dextromethorphan guaiacol ether oral liquid completed the application materials. The consistency evaluation project continued to advance. During the reporting period, the company carried out 10 consistency evaluation projects for injections and 4 consistency evaluation projects for oral solid preparations.
3. Coordinated development and give full play to the advantages of chemical medicine industry chain
Relying on the three bases of Jiangsu, Chongqing and Hainan, the company focuses on high value-added generic drugs and characteristic drugs, and the industrial chain layout structure has been basically established. Kaiyuan pharmaceutical of Yancheng intermediate base in Jiangsu Province has completed the transformation construction of the whole process automatic control, realizing the resumption of work and production. Jiangsu hankuo 4-AA silanide market is in short supply. Chongqing Wuyang API base has further optimized the variety wiring and reasonably reduced the construction cost. The first phase of the project has entered a comprehensive closing stage. Guilin Haiyao, DG workshop and DK workshop newly built in Hainan preparation base have completed 3Q verification and process verification, passed GMP compliance on-site inspection, and the workshops have been put into use one after another.
In order to further improve the utilization rate of preparation production line, the company actively develops the market and carries out entrusted processing business: it has signed entrusted processing agreements with 5 enterprises, and all projects are in the stage of workshop transformation and process trial production. The resumption of production of Xiaochaihu granules has been carried out, and the on-site verification has been completed.
4. Pay close attention to management and realize cost reduction and cost control
We will continue to promote the reform of the three systems and optimize the personnel structure. Implement contractual management, implement “two books and one method”, improve the management methods of performance assessment, salary and welfare of managers, and the post and staffing plan of functional departments. Establish a chapter and system, promote the work related to the “abolishment, reform and interpretation” of the company’s system, newly formulate 12 systems such as procurement and bidding, and improve and revise 10 systems.
Carry out benchmarking and improvement actions, aim at the leading level, find gaps, make up weaknesses and strengths. Implement the special work of management improvement, establish a management improvement working group, and the leaders in charge of each business take the lead to strengthen the management of the business sector from the five sectors of production, R & D, sales, capital and two non sectors, so as to comprehensively improve the level of management ability.
5. Sales breakthrough and strive to control expenses incrementally
Optimize marketing organization and improve per capita labor efficiency. Adopt the flat management structure of marketing company, province and region, carry out monthly profit and loss analysis and quarterly assessment, and optimize and eliminate according to the results. Through continuous optimization, adjustment of organizational structure and personnel structure and improvement of salary assessment methods, the per capita labor efficiency of sales companies has increased by about 55.15% compared with 2020.
Sort out key product markets and formulate incremental policies. Implement the incentive measures to the front line, expand the product layout, and strive to seek increment in the existing market and development in the blank market. Link the production plan of raw materials and preparations to ensure the supply of main products; Effectively improve product quality, closely follow the bidding linkage of local markets, and coordinate the bid winning and falling scheme.
6. Prevent and control risks and build the cornerstone of development
Strictly control financial risks and strengthen financial control: strictly control the risk of capital payment through highly centralized and unified settlement of funds, so as to realize the rigid control of comprehensive budget; Set up a special working group for “two funds” pressure reduction to incorporate the effectiveness of “two funds” pressure reduction into the internal business performance assessment; Formulate the collection policy of accounts receivable and implement the strict responsibility system of accounts receivable; Improve internal control mechanism, standardize and improve inventory management.
Strengthen internal control and improve the system: verify the integrity of internal control defect prevention and risk control measures, and add or revise the management system targeted. 12 systems including the measures for the administration of financing guarantee and the measures for the administration of Hainan Haiyao Co.Ltd(000566) compliance have been revised and issued. Improve the risk management process, form a closed-loop management of risk management information collection, risk assessment, risk monitoring, supervision and improvement, and improve the risk prevention system. Carry out safety and environmental protection rectification in an orderly manner: revise and improve the EHS management manual, comprehensive emergency plan for production safety accidents and emergency response plan for emergencies according to the new production safety law and in combination with the actual situation. We have carried out three-year special rectification actions for work safety and environmental protection improvement actions, completed a total of 26 special rectification tasks, continuously improved the software and hardware management level of safety accessories and safety measures, and strengthened the operation and maintenance management of environmental protection facilities and equipment.
(II) main business
According to the industry classification guidelines for listed companies (revised in 2012) issued by the CSRC, the company belongs to the pharmaceutical manufacturing industry. Focusing on the overall health layout, the company covers the fields of intermediates, APIs, chemicals, medical devices, modern traditional Chinese medicine, biomedicine and medical services. At present, the company focuses on the R & D, production and sales of drugs and medical devices.
1. Main products
The company’s main products throughout the year include six series, including antibiotic series, gastrointestinal drug series, antitumor drug series, cochlear implant series, API and intermediate series matched with the preparation and other products.
Category product main function / product use
Upper and lower respiratory tract infection, urinary tract infection, peritonitis and other abdominal infections caused by sensitive bacteria for injection
Cefoxitin sodium, intraluminal and pelvic infection, sepsis, gynecological infection, bone, joint and soft tissue infection, heart
Endometritis, etc
Lower respiratory tract infection, urinary tract infection, abdominal infection, pelvic infection and abortion caused by sensitive bacteria for injection
Cefazoxime sodium, skin and soft tissue infections, bone and joint infections, Streptococcus pneumoniae or influenza Haemophilus
Meningitis and simple gonorrhea caused by bacteria
Respiratory tract, ear, nose and throat infection, urinary tract infection, skin and soft tissue infection caused by sensitive bacteria for injection
Cefuroxime sodium infection, sepsis, meningitis, gonorrhea, bone and joint infection, etc
Lower respiratory tract infection, urinary tract and biliary tract infection caused by sensitive pathogenic bacteria for injection, as well as abdominal infection
Antibiotic series: ceftriaxone sodium, pelvic infection, skin and soft tissue infection, bone and joint infection, sepsis, meningitis, etc
Infection prevention during operation, simple gonorrhea, etc
Infection of respiratory system, urinary system, otolaryngology, skin and soft tissue caused by sensitive bacteria of cefaclor granules
etc.
Various infections caused by sensitive aerobic gram-negative bacteria of aztreonam for injection, such as urinary tract infection and lower respiratory tract infection
Skin infection, sepsis, intra-abdominal infection, gynecological infection, postoperative wound, burn, ulcer, etc
Skin and soft tissue infection, etc
Meropenem for injection infection caused by one or more meropenem sensitive bacteria: pneumonia (including in-hospital infection)
Acquired pneumonia), urinary tract infection, gynecological infection (such as endometritis and pelvic inflammation)
Skin and soft tissue infection, meningitis, sepsis, etc
Gastrointestinal medicine series changweikang series clearing heat, removing dampness and removing stagnation are used for acute gastroenteritis, food stagnation and stomachache
First line and combined treatment of ovarian cancer, breast cancer and non-small cell lung cancer with Paclitaxel injection of anti-tumor drug series, AIDS
Second line treatment of (AIDS) – related Kaposi’s sarcoma
Rez-i cochlear implant for severe and extremely severe sensorineural adult postlingual deafness
Lci-20pi cochlear implant is suitable for binaural severe or very severe sound sensation aged more than 12 months (including 12 months)
Cochlear implant deafness patients with lci-21pi cochlear implant
In vivo, lsp-20b cochlear implant sound
Sound processor, lsp-20c artificial ear
Cochlear sound processor
API and its 7-anca cephalosporin antibiotic intermediates can be used for the production and processing of ceftizoxime, etc
Intermediate series 4-AA is used for the production and processing of meropenem and other penem antibiotics
Cefoxitin sodium is used in the production of cefoxitin sodium preparation
Cefoxitin acid is used as raw material in the production of cefoxitin
Ceftizoxime sodium is used in the production of ceftizoxime sodium preparations
Aztreonam is used to produce aztreonam preparation
